Fisher & Paykel HealthcareASX:FPH +0.13%86 Median PS Value is A$29.09 as of Jun. 26, 2026, which is 100% below its 10-year median of 1.46. GuruFocus rates ASX:FPH with a GF Score™ of 86/100 and a GF Value™ of A$36.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 338 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks worse than 80.47% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Fisher & Paykel Healthcare's Median PS Value or its related term are showing as below:
ASX:FPH'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.02 Med: 1.46 Max: 2.25
Current: 1.09
During the past 13 years, the highest Price to Median PS Value of Fisher & Paykel Healthcare was 2.25. The lowest was 1.02. And the median was 1.46.
ASX:FPH's Price-to-Median-PS-Value is ranked worse than 80.47% of 338
companies
in the Medical Devices & Instruments industry
Industry Median: 0.71
vs ASX:FPH: 1.09
Fisher & Paykel Healthcare (ASX:FPH) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Fisher & Paykel Healthcare's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
31.57
/
29.09
=
1.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare Median PS Value Related Terms
Fisher & Paykel Healthcare Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:FPH vs ISRG, BDX, MDLN: Median PS Value Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 8.6449.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$3.365.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a Median PS Value of A$29.09 as of Jun. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Fisher & Paykel Healthcare and its competitors. This is 1892% above median its historical median of 1.46. Over the past decade, Fisher & Paykel Healthcare's Median PS Value has ranged from 1.02 to 2.25. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #272 out of 338 companies in the Medical Devices & Instruments industry, placing it in the top 80.5%.
Is Fisher & Paykel Healthcare's Median PS Value too high?
Fisher & Paykel Healthcare's current Median PS Value of A$29.09 is 1892% above median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 2.25. Based on the distribution chart, Fisher & Paykel Healthcare ranks #272 out of 338 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Median PS Value compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #272 out of 338 companies for Median PS Value. This places Fisher & Paykel Healthcare in the lower half of its industry. The industry median Median PS Value is 0.71. Historically, Fisher & Paykel Healthcare's own Median PS Value has ranged from 1.02 to 2.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Median PS Value is A$29.09, which is 1892% above median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.31, compared to a current price of A$31.57 — trading 13.1% below its estimated fair value. The current Median PS Value is A$29.09, which is 1892% above median its 10-year median of 1.46. Fisher & Paykel Healthcare's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Median PS Value is A$29.09 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$31.57 is trading 13.1% below its estimated GF Value™ of A$36.31.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:FPH:
Median PS Value: A$29.09 (1892% above median its 10-year median of 1.46)
GF Value™: A$36.31 vs. price of A$31.57 (13.1% below fair value)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
86GF Score
Get the complete analysis for ASX:FPH
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
